Abstract:Dysregulated HGF/c‐Met signalling has been associated with many human cancers, poor clinical outcomes, and even resistance acquisition to some approved targeted therapies. As such, c‐Met kinase has emerged as a attractive target for anticancer drug discovery. Herein, a series of 6,7‐disubstitued‐4‐(2‐fluorophenoxy)quinoline derivatives bearing α‐acyloxycarboxamide moiety were designed, synthesized via Passerini reaction as the key step, and evaluated for their in vitro biological activities against c‐Met kinase and five selected cancer cell lines. The preliminary structure‐activity relationship demonstrated that α‐acyloxycarboxamide as the 5‐atom linker maintained the potent antitumor potency. Among these compounds, compound 25s (c‐Met IC50 = 4.06 nM) was identified as the most promising lead compound and displayed the most potent antiproliferative activities against A549, HT‐29 and MDA‐MB‐231 cell lines with IC50 of 0.39, 0.20, and 0.58 μM, which were 1.3‐, 1.4‐ and 1.2‐fold superior to foretinib, respectively. The further studies indicated that compound 25s can induce apoptosis of A549 cells and arrest efficiently the cell cycle distribution in G2/M phase of A549 cells. Moreover, compound 25s can also inhibit of c‐Met phosphorylation in A549 cells by a dose‐dependent manner. Collectively, these results indicated that compound 25s could be a potential anticancer lead compound deserving for further development.This article is protected by copyright. All rights reserved.

Discovery of Imidazopyridine Derivatives As Novel C-Met Kinase Inhibitors: Synthesis, SAR Study, and Biological Activity

Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors

Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors

Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity

Pyridazinone Derivatives Displaying Highly Potent and Selective Inhibitory Activities Against C-Met Tyrosine Kinase.

Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (C-Met) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(quinolin-6-ylmethyl)-1h-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1h-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment Of

Discovery Of Novel C-Met Inhibitors Bearing A 3-Carboxyl Piperidin-2-One Scaffold

Discovery and SAR Study of C-Met Kinase Inhibitors Bearing an 3-Amino-benzo[d]isoxazole or 3-Aminoindazole Scaffold.

Discovery of Novel C-Met Kinase Inhibitors Bearing a Thieno[2,3-D]pyrimidine or Furo[2,3-D]pyrimidine Scaffold.

Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors

Structure-guided design and development of novel N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors

Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors

Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors

Structure-based Discovery of Novel 4-(2-fluorophenoxy)quinoline Derivatives As C-Met Inhibitors Using Isocyanide-Involved Multicomponent Reactions.

Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors

Discovery of Novel Inhibitors for C-Met by Virtual Screening and Pharmacophore Analysis

Design, synthesis, biological evaluation, and docking studies of novel triazolo[4,3- b]pyridazine derivatives as dual c-Met/Pim-1 potential inhibitors with antitumor activity

Design, Synthesis and Biological Evaluation of Sulfonylamidines As Potent C-Met Inhibitors by Enhancing Hydrophobic Interaction.

Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.

Biological activity, Molecular Docking Studies and Molecular Dynamics Simulations of 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b] indoles as c-Met inhibitors

Design, Synthesis and Biological Evaluation of Novel α‐Acyloxycarboxamide‐Based Derivatives as c‐Met Inhibitors